Smoking Cessation
Keywords:
Smoking cessation, E-cigarette cessation, Nicotine addiction, Counseling, Medication, Herbal medicineAbstract
Smoking and e-cigarette use are major public health problems globally and in Thailand. Although conventional smoking prevalence in Thailand has slightly decreased, it remains high, alongside a concerning rise in e-cigarette use, particularly among adolescents and young adults. Use of these products severely impacts health, increasing risks of cardiovascular disease, cancer, and respiratory diseases. Smoking cessation is therefore crucial. Nicotine addiction is a complex neurobiological process; withdrawal symptoms upon cessation pose significant barriers. Effective cessation involves combining counseling (e.g., the 5A’s approach) and pharmacotherapy. While no medications are currently specifically approved for e-cigarette cessation, existing smoking cessation medications like nicotine replacement therapy (NRT), Bupropion, Varenicline, and Nortriptyline can be applied to manage nicotine withdrawal and improve quit rates. Herbal medicines like Vernonia cinerea have preliminary but require more evidence. Smoking cessation requires commitment and determination. Combining counseling and medication increases the chances of successfully quitting. Smoking cessation not only reduces disease risk but also enhances quality of life and lowers healthcare costs.
References
ศูนย์วิจัยและจัดการความรู้เพื่อการควบคุมยาสูบ (ศจย.). รายงานสถานการณ์การควบคุมการบริโภคยาสูบของประเทศไทย พ.ศ. 2565. กรุงเทพฯ: คณะสาธารณสุขศาสตร์ มหาวิทยาลัยมหิดล; 2565.
สำนักงานสถิติแห่งชาติ. การสำรวจพฤติกรรมการสูบบุหรี่และการดื่มสุราของประชากร พ.ศ. 2564. กรุงเทพฯ: สำนักงานสถิติแห่งชาติ; 2564.
สำนักงานคณะกรรมการควบคุมเครื่องดื่มแอลกอฮอล์และยาสูบ. รายงานการติดตามสถานการณ์การบริโภคผลิตภัณฑ์ยาสูบรูปแบบใหม่ (บุหรี่ไฟฟ้า) ในประเทศไทย พ.ศ. 2565. กรุงเทพฯ: กรมควบคุมโรค กระทรวงสาธารณสุข; 2565.
World Health Organization. WHO report on the global tobacco epidemic protect people from tobacco smoke; [Internet]. 2023. Available from: https://iris.who.int/handle/10665/372043
United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General [Internet]. Washington (DC): US Department of Health and Human Services;2020. PMID:32255575.
Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008;57:1226-8.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.
National Academies of Sciences, Engineering, and Medicine. Public Health Consequences of E-Cigarettes. Washington, DC: The National Academies Press; 2018.
Centers for Disease Control and Prevention (CDC). Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products [Internet]. Atlanta (GA): CDC; 2021 Oct 25 [last updated; cited 2025 Apr 9]. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence:2008 Update. Clinical Practice Guideline. Rockville (MD): US Department of Health and Human Services. Public Health Service; 2008.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119-27.
Foulds J, Veldheer S, Yingst J, Hrabovsky S, Wilson SJ, Nichols TT, Eissenberg T. Development of a questionnaire for assessing dependence on electronic cigarettes: The Penn State Electronic Cigarette Dependence Index. Nicotine Tob Res. 2015;17:186-92
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing. 2013.
Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;31: CD000165.
Heshmati J, Lankarani K, Majidi A, Qasemi A, Morovatdar N, Ebrahimi M, et al. Vaping cessation interventions: a systematic review and meta-analysis. Tob Control. 2025.
Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4:CD013308.
Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792-8.
Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020;4: CD000031.
Lindson N, Theodoulou A, Ordóñez-Mena JM, Fanshawe TR, Sutton AJ, Livingstone-Banks J, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: a network meta-analysis. Cochrane Database Syst Rev. 2023;9:CD015216.
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-20.
Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018;178:622-31.
Courtney RJ, McRobbie H, Tutka P, Weaver NA, Petrie D, Mendelsohn CP, et al. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021;326:56-64.
Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med. 2002;346:506-12.
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Watson ER, Sands SB, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-7.
Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3:235-41.
Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Nortriptyline for smoking cessation. Cochrane Database Syst Rev. 2014;(1):CD000115.
Tutka P, Vinnikov D, Courtney RJ, Benowitz NL. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction. 2019;114:1951-69.
Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med. 2009;150:447-54.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S; Varenicline Cardiovascular Disease Study Group. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221-9.
West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011;365:1193-200. doi:10.1056/NEJMoa1102035.
Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax. 2013;68:1037-42. doi:10.1136/thoraxjnl-2012-203035. PubMed PMID:23404838.
Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004; CD000058. doi:10.1002/14651858.CD000058.pub2. PubMed PMID:15266422; PMCID:PMC7038651.
Wongwiwatthananukit S, Benjanakaskul P, Songsak T, Suwanamajo S, Verachai V. Efficacy of Vernonia cinerea for Smoking Cessation. J Health Res [internet]. 2018 Nov. 20 [cited 2025 Aug 21];23:31-6. available from: https://he01.tci-thaijo.org/index.php/jhealthres/article/view/156327
Supakit V, Pukdeebumroong K, Sangkum P, Silarak T, Dhippayom T. Effectiveness of Vernonia cinerea (L.) Less. for smoking cessation: a systematic review and meta-analysis. Complement Ther Med. 2018;41:117-23.
Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev. 2012;CD000124. doi:10.1002/14651858.CD000124.pub2. PubMed PMID:22336780; PMCID:PMC 7043274.
Rose JE, Behm FM. Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug Alcohol Depend. 1994;34:225-9. doi:10.1016/0376-8716(94)90160-0. PubMed PMID: 8033760.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
